|
|
|
|
|
|
最高研发阶段临床3期 |
首次获批国家/地区- |
首次获批日期- |
|
|
在研机构- |
|
在研适应症- |
|
最高研发阶段终止 |
首次获批国家/地区- |
首次获批日期- |
靶点- |
|
在研机构- |
|
在研适应症- |
|
最高研发阶段终止 |
首次获批国家/地区- |
首次获批日期- |
Phase I Trial to Determine Optimal Phase II Dose of the Oral Dual CAIX Inhibitor/ Radiosensitizer
This is a Phase I multicenter, open-label, dose-escalation study of DTP348. DTP 348 is an oral dual drug with two mechanisms of action:
carbonic anhydrase IX inhibitor which acidifies the intracellular pH through the sulfamide components
radio sensitizer of hypoxic cells through its 5-nitroimidazole moiety
The study will be conducted in 2 parts. The phase I trials will be on the standard 3+3 design first as single agent then combined with radiotherapy:
A single agent dose-escalation phase in patients with solid tumours.
A dose-escalation phase in patients with HNSCC in combination with radiotherapy
The main objective is to determine the recommended phase II dose of DTP348 in combination with radiotherapy
100 项与 Stichting Maastricht Radiation Oncology MAASTRO Clinic 相关的临床结果
0 项与 Stichting Maastricht Radiation Oncology MAASTRO Clinic 相关的专利(医药)
100 项与 Stichting Maastricht Radiation Oncology MAASTRO Clinic 相关的药物交易
100 项与 Stichting Maastricht Radiation Oncology MAASTRO Clinic 相关的转化医学